• Welcome, Guest. Please login or register.
    June 01, 2020, 01:20:27 AM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal © A. Battaglia 2019





55292 Posts in 5909 Topics by 6204 Members
Latest Member: pareshdas1985

Forum Tip: 
You can now simply type thalpal.com into your browser and it will take you to this site. Tell your friends about this easy-to-remember name.
www.thalpal.com
« previous next »
Pages: 1 Go Down Print
Author Topic: Hydroxyurea and phlebotomy in Sickle Cell  (Read 2272 times)
ironjustice
Junior Member
***
Offline Offline

Posts: 132


« on: March 21, 2016, 12:13:04 PM »

The iron BEFORE disease hypothesis? The use of the iron chelator hydroxyurea, WITH phlebotomy, in those who do not respond to hydroxyurea alone?

Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin sickle cell disease.
Summarell CC1, Sheehan VA2.
Exp Biol Med (Maywood). 2016 Mar 17. pii: 1535370216639737.
Abstract
Hydroxyurea is an excellent therapeutic agent for the pharmacological induction of HbF in patients with sickle cell disease (SCD). However, all completed clinical trials of hydroxyurea have excluded patients with hemoglobin SC (HbSC) disease. HbSC differs significantly in pathophysiology from HbSS, as HbC does not sickle, but instead causes cellular dehydration which potentiates sickling of HbS. Many severely affected HbSC patients have been placed on hydroxyurea on a case by case basis, but there are no large scale prospective data on safety or efficacy of hydroxyurea in this subset of patients with SCD. Here, we report a case series of 14 pediatric patients with HbSC treated to maximum tolerated dose (MTD) with hydroxyurea. Those who failed to show clinical improvement after at least six months at MTD were offered phlebotomy in addition to hydroxyurea. Five out of 11 patients with HbSC who achieved MTD failed to demonstrate clinical improvement on hydroxyurea. Of the four placed on dual hydroxyurea and phlebotomy therapy, all showed at least partial clinical improvement. Percent dense red blood cells (%DRBC) were measured via an ADVIA hematology analyzer. A marked rise in percent dense cells preceded clinical complications in three patients. Dual therapy with hydroxyurea and phlebotomy may be an effective approach to patients with HbSC that do not experience improvement with hydroxyurea alone. Monitoring of %DRBC may predict adverse events and aid in assessing hydroxyurea compliance. Large scale clinical trials are needed to evaluate the safety and efficacy of hydroxyurea and hydroxyurea with phlebotomy in patients with HbSC disease.

© 2016 by the Society for Experimental Biology and Medicine.

KEYWORDS:
Hemoglobin SC disease; hydroxyurea; phlebotomy; red blood cell density
PMID: 26993671
Logged
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!